Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue attributed to variable BCMA expression, BCMA downregulation, and heterogeneity of tumor antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Jieyun, Li, Zhenyu, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240779/
https://www.ncbi.nlm.nih.gov/pubmed/37277826
http://dx.doi.org/10.1186/s13045-023-01461-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240779/
https://www.ncbi.nlm.nih.gov/pubmed/37277826
http://dx.doi.org/10.1186/s13045-023-01461-1

Ejemplares similares